Immunogenicity and autoimmunity during anti-TNF therapy.
Autoimmun Rev
; 12(7): 703-8, 2013 May.
Article
de En
| MEDLINE
| ID: mdl-23207283
ABSTRACT
The introduction of anti-tumour necrosis factor (TNF) agents for the treatment of rheumatoid arthritis (RA), Crohn's disease (CD) or spondyloarthritis (SpA) has revolutionised the therapeutic approach to patients with active disease failing to respond to conventional therapy. However, some of the patients treated with selective TNF inhibitors may develop autoantibodies, such as antinuclear antibodies (ANAs) and anti-double-stranded DNA (anti-dsDNA) antibodies. Furthermore, anti-phospholipid antibodies, which are mainly detected by means of anti-cardiolipin assays, have been found in RA patients receiving TNF blockers. There have also been a number of reports of the development of anti-drug antibodies, of which those against infliximab can interfere with the drug's pharmacokinetics (and therefore its effects), and may also cause acute and delayed infusion and injection site reactions. The onset of autoimmune diseases during biological treatment is rare, but it needs to be promptly recognised in order to plan appropriate patient management. The addition of an immunosuppressive drug can reduce the induction of anti-TNF antibodies.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Auto-immunité
/
Facteur de nécrose tumorale alpha
/
Anticorps
Limites:
Humans
Langue:
En
Journal:
Autoimmun Rev
Sujet du journal:
ALERGIA E IMUNOLOGIA
Année:
2013
Type de document:
Article
Pays d'affiliation:
Italie